364 related articles for article (PubMed ID: 27888056)
21. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
22. Sclerostin, an osteocytes-derived bone-forming inhibitor.
Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
[TBL] [Abstract][Full Text] [Related]
23. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
24. Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein.
Gould NR; Williams KM; Joca HC; Torre OM; Lyons JS; Leser JM; Srikanth MP; Hughes M; Khairallah RJ; Feldman RA; Ward CW; Stains JP
Elife; 2021 Mar; 10():. PubMed ID: 33779549
[TBL] [Abstract][Full Text] [Related]
25. Pigment epithelium derived factor suppresses expression of Sost/Sclerostin by osteocytes: implication for its role in bone matrix mineralization.
Li F; Song N; Tombran-Tink J; Niyibizi C
J Cell Physiol; 2015 Jun; 230(6):1243-9. PubMed ID: 25363869
[TBL] [Abstract][Full Text] [Related]
26. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
27. Osteocyte deficiency in hip fractures.
Delgado-Calle J; Arozamena J; García-Renedo R; García-Ibarbia C; Pascual-Carra MA; González-Macías J; Riancho JA
Calcif Tissue Int; 2011 Oct; 89(4):327-34. PubMed ID: 21874545
[TBL] [Abstract][Full Text] [Related]
28. Role and mechanism of action of sclerostin in bone.
Delgado-Calle J; Sato AY; Bellido T
Bone; 2017 Mar; 96():29-37. PubMed ID: 27742498
[TBL] [Abstract][Full Text] [Related]
29. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
30. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody.
Morrell AE; Robinson ST; Ke HZ; Holdsworth G; Guo XE
Bone; 2021 Aug; 149():115967. PubMed ID: 33892178
[TBL] [Abstract][Full Text] [Related]
31. Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.
Haynes KR; Tseng HW; Kneissel M; Glant TT; Brown MA; Thomas GP
BMC Musculoskelet Disord; 2015 Nov; 16():368. PubMed ID: 26612313
[TBL] [Abstract][Full Text] [Related]
32. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion.
Wijenayaka AR; Yang D; Prideaux M; Ito N; Kogawa M; Anderson PH; Morris HA; Solomon LB; Loots GG; Findlay DM; Atkins GJ
Mol Cell Endocrinol; 2015 Sep; 413():157-67. PubMed ID: 26112182
[TBL] [Abstract][Full Text] [Related]
33. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.
Chan BY; Fuller ES; Russell AK; Smith SM; Smith MM; Jackson MT; Cake MA; Read RA; Bateman JF; Sambrook PN; Little CB
Osteoarthritis Cartilage; 2011 Jul; 19(7):874-85. PubMed ID: 21619935
[TBL] [Abstract][Full Text] [Related]
34. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
35. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
[TBL] [Abstract][Full Text] [Related]
36. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway.
Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ
Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159
[TBL] [Abstract][Full Text] [Related]
37. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
Pietrzyk B; Smertka M; Chudek J
Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
[TBL] [Abstract][Full Text] [Related]
38. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways.
Bouaziz W; Funck-Brentano T; Lin H; Marty C; Ea HK; Hay E; Cohen-Solal M
Arthritis Res Ther; 2015 Feb; 17(1):24. PubMed ID: 25656376
[TBL] [Abstract][Full Text] [Related]
39. TIEG and estrogen modulate SOST expression in the murine skeleton.
Subramaniam M; Pitel KS; Bruinsma ES; Monroe DG; Hawse JR
J Cell Physiol; 2018 Apr; 233(4):3540-3551. PubMed ID: 29044507
[TBL] [Abstract][Full Text] [Related]
40. Sclerostin: recent advances and clinical implications.
Honasoge M; Rao AD; Rao SD
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
